InvestorsHub Logo
Followers 54
Posts 4438
Boards Moderated 0
Alias Born 08/21/2015

Re: bigjay187 post# 19232

Thursday, 04/06/2017 9:13:06 AM

Thursday, April 06, 2017 9:13:06 AM

Post# of 74527
I know Otiko uses the Phillips/Keough patent-pending delivery system because he states this fact in many places designed for shareholders.

The Annual Report needs to clearly convey his use of this delivery system, the terms, and rights assigned by product name.

He went from an exclusive to non-exclusive license agreement with Phillips in late 2016. This is for Viabecline which is based on the patent-pending delivery system.